BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting…
20 analysts rate BNTX Buy on consensus.
Consensus price target: $117.06 (+32.85% upside from $88.12)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Sahin Ugur 10 percent owner, Chief Executive Officer | Oct 9, 2026 | Sale | 36,209 | $3.45M |
| Sahin Ugur 10 percent owner, Chief Executive Officer | Oct 8, 2026 | Sale | 27,000 | $2.49M |
| Sahin Ugur 10 percent owner, Chief Executive Officer | Oct 7, 2026 | Sale | 24,000 | $2.3M |
| Sahin Ugur 10 percent owner, Chief Executive Officer | Oct 6, 2026 | Sale | 21,000 | $2.03M |
| Sahin Ugur 10 percent owner, Chief Executive Officer | Oct 5, 2026 | Sale | 72,000 | $7M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $3.09B | +0.2% | $-1.22B |
| 2024 | $3.08B | -27.96% | $-745.46M |
| 2023 | $4.28B | -77.94% | $1.04B |
Stock data for BNTX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics